Skip to main content

Leica Bio, ACD Ink Co-marketing Agreement

NEW YORK (GenomeWeb) – Leica Biosystems and Advanced Cell Diagnostics today announced a co-marketing agreement covering their respective technologies to provide an integrated and fully automated in situ hybridization solution.

The firms will co-market ACD's RNAscope LS ISH assays with Leica's BOND RX research staining platform. The assays provide researchers a method for robust single RNA molecule detection for formalin-fixed, paraffin-embedded tissue. Since their introduction three years ago, biotech firms have used the RNAscope assays for drug discovery, translational research, and the development of clinical and companion diagnostic tests, the companies said.

Financial and other terms of the deal were not disclosed.

Earlier this week, ACD said that it received ISO 13485-2003 certification for its diagnostic kits, enabling it to launch the RNAscope product lines in Europe.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.